KR20250024530A - 5t4 결합제 및 이의 용도 - Google Patents

5t4 결합제 및 이의 용도 Download PDF

Info

Publication number
KR20250024530A
KR20250024530A KR1020247040741A KR20247040741A KR20250024530A KR 20250024530 A KR20250024530 A KR 20250024530A KR 1020247040741 A KR1020247040741 A KR 1020247040741A KR 20247040741 A KR20247040741 A KR 20247040741A KR 20250024530 A KR20250024530 A KR 20250024530A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040741A
Other languages
English (en)
Korean (ko)
Inventor
보니 해머
제프리 엔 히가키
시마 칸탁
찰스 카플란
Original Assignee
엑셀리시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑셀리시스, 인코포레이티드 filed Critical 엑셀리시스, 인코포레이티드
Publication of KR20250024530A publication Critical patent/KR20250024530A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247040741A 2022-05-13 2023-05-10 5t4 결합제 및 이의 용도 Pending KR20250024530A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341944P 2022-05-13 2022-05-13
US63/341,944 2022-05-13
PCT/US2023/066819 WO2023220626A2 (en) 2022-05-13 2023-05-10 5t4 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
KR20250024530A true KR20250024530A (ko) 2025-02-18

Family

ID=88731098

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040741A Pending KR20250024530A (ko) 2022-05-13 2023-05-10 5t4 결합제 및 이의 용도

Country Status (16)

Country Link
US (1) US20250326858A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522660A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518493A (cg-RX-API-DMAC7.html)
KR (1) KR20250024530A (cg-RX-API-DMAC7.html)
CN (2) CN119546643A (cg-RX-API-DMAC7.html)
AU (1) AU2023267764A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252305A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024003442A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024015383A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240489A (cg-RX-API-DMAC7.html)
DO (1) DOP2024000234A (cg-RX-API-DMAC7.html)
IL (1) IL316788A (cg-RX-API-DMAC7.html)
MX (1) MX2024013871A (cg-RX-API-DMAC7.html)
PE (1) PE20251275A1 (cg-RX-API-DMAC7.html)
TW (1) TW202400639A (cg-RX-API-DMAC7.html)
WO (1) WO2023220626A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025180472A1 (zh) * 2024-02-28 2025-09-04 惠和生物技术(上海)有限公司 单克隆抗体分子及其用途
WO2026010986A1 (en) * 2024-07-05 2026-01-08 Solve Therapeutics, Inc. 5t4-binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG170091A1 (en) * 2006-03-10 2011-04-29 Wyeth Corp Anti-5t4 antibodies and uses thereof
WO2016034666A1 (en) * 2014-09-04 2016-03-10 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
KR20220030934A (ko) * 2019-05-31 2022-03-11 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 항-gal9 면역-억제 결합 분자

Also Published As

Publication number Publication date
PE20251275A1 (es) 2025-05-14
JP2025518493A (ja) 2025-06-17
EP4522660A4 (en) 2026-04-29
CN119546643A (zh) 2025-02-28
WO2023220626A2 (en) 2023-11-16
CL2025002572A1 (es) 2025-10-03
WO2023220626A3 (en) 2023-12-14
CA3252305A1 (en) 2023-11-16
CN120607619A (zh) 2025-09-09
TW202400639A (zh) 2024-01-01
DOP2024000234A (es) 2025-02-28
US20250326858A1 (en) 2025-10-23
MX2024013871A (es) 2024-12-06
EP4522660A2 (en) 2025-03-19
CL2024003442A1 (es) 2025-02-28
CO2024015383A2 (es) 2025-02-04
CR20240489A (es) 2025-01-07
AU2023267764A1 (en) 2024-11-21
IL316788A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP2021153585A (ja) 抗ガレクチン−9抗体及びその使用
JP7840312B2 (ja) 多重特異性結合性作用剤およびその使用
US20250197502A1 (en) Multispecific binding agents and uses thereof
JP7627258B2 (ja) 抗bcma抗体、その抗原結合断片、及びそれらの医療用途
US20250326858A1 (en) 5t4 binding agents and uses thereof
US20230357391A1 (en) Cd47 binding agents and uses thereof
JP7854423B2 (ja) Pd-l1結合性作用剤およびその使用
JP2025537255A (ja) 抗アルファ5インテグリン抗体及びその使用
TW202221038A (zh) 抗trop-2抗體、其抗原結合片段或其突變體、及其醫藥用途
CN118974098A (zh) 多重特异性结合剂及其用途
WO2025230866A1 (en) Anti-alpha5 integrin antibodies and uses thereof
HK40039874B (en) Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000